Pharmacological Therapy in Osteoarthritis
Article information
J Korean Med Assoc. 2003;46(11):958-964
Publication date (electronic) : 2003 November 30
doi :
https://doi.org/10.5124/jkma.2003.46.11.958
Abstract
Osteoarthritis (OA) is a common, chronic, and painful disorder characterized by cartilage loss. It is the most common among all rheumatic disorders and is a major cause of disability. OA can be managed with a variety of pharmacological therapies, including acetaminophen, traditional nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, intra-articular steroids, viscosupplements, glucosamine, chondroitin sulfate, and capsaicin. In this review, I describe the clinical efficacy and side effects of these pharmaceuticals and review disease-modifying osteoarthritis drugs (DMOAD), such as glucosamine, diacerein, and avocado/soybean unsaponifiables, of which the clinical efficacy still remains to be determined.
Keywords: Osteoarthritis; Acetaminophen; Nonsteroidal anti-inflammatory drug; Disease modifying osteoarthritis drug
References
1. American College of Rheumatology subcommittee on osteoarthritis guidelines. [Special Articles] Recommendation for the medical management of osteoarthritis of the hip and knee : 2000 update. Arthirtis Rheum 2000. 431905–1915.
2. NIH Conference. Osteoarthritis : New Insights, part I : The disease and its risk factors. Ann Intern Med 2000. 133635–646.
3. Sowers MF. Epidemiology of risk factors for osteoarthritis : systemic factors. Curr Opin Rheummatol 2001. 13447–451.
4. Sharma L. Local factors in osteoarthritis. Curr Opin Rheummatol 2001. 13441–446.
5. Doherty M. Risk factors for progression of knee osteoarthritis. Lancet 2001. 358775–776.
6. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998. 41(8)1343–1355.
7. Jacobsson , Lennart TH. The epidemiology of osteoarthritis in the peripheral joints : definitions of osteoarthritis in the knee and hand. Ann Rheum Dis 1996. 55(9)656–658.
8. Schouten Jan SAG, de Bie RA, Swaen G. An update on the relationship between occupational factors and osteoarthritis of the hip and knee. Curr Opin Rheummatol 2002. 1489–92.
9. Pelletier JP, Johanne MP, Abramson SB. Osteoarthritis, an inflammatory disease. Potential complication for the selection of new therapeutic targets. Arthritis Rheum 2001. 41(6)1237–1247.
10. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000. 43(9)1905–1915.
11. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, et al. NIH conference, New insights, Part 2 : Treatment approaches. Ann Intern Med 2000. 133726–737.
12. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, et al. EULAR recommendations for the management of knee osteoarthritis : report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2000. 59936–944.
13. Jubb RW. Oral and intra-articular remedies : Review of papers published from March 2001 to February 2002. Curr Opin Rheummatol 2002. 14597–602.
14. Hawkey CJ. COX-2 inhibitors. Lancet 1999. 353307–314.
15. Maxime D, Minh N, Laurent B, Bernard M, Eric V, Michel L. Evaluation of the structure-modifying effects of diacerein in hip osteoarthiritis : ECHODIAH, a three-year, placebo-controlled trial. Arthirtis Rheum 2001. 442539–2547.
16. Forent R, Oliver B, Olivier E, Michel C, Yves H, Jean-Yves R. Structural and symptomatic efficacy of glucosamine and chodroitin in knee osteoarthritis : A comprehensive meta-analysis. Arch Intern Med 2003. 1631514–1522.
17. Michel L, Emmanuel M, Christian C, Renée-Liliane D. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care Res 2003. 47(1)50–58.
Article information Continued
Copyright © 2003 Korean Medical Association
